Genfit SA ( (GNFT) ) has provided an announcement.
GENFIT announced that Ipsen will present positive Phase 2 data for elafibranor in treating Primary Sclerosing Cholangitis (PSC) at the EASL Congress on May 10, 2025. The ELMWOOD trial results demonstrated significant efficacy and a favorable safety profile of elafibranor, showing dose-dependent reductions in alkaline phosphatase and improvements in liver fibrosis markers. This reinforces elafibranor’s potential in addressing serious liver diseases, enhancing GENFIT’s position in the biopharmaceutical industry.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s stock score reflects significant financial challenges, particularly in profitability and cash flow. While the stock may be undervalued, negative technical trends and the absence of earnings call guidance contribute to a cautious outlook. Improvements in financial health and clearer strategic direction are needed for a more favorable assessment.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on improving the lives of patients with rare and life-threatening liver diseases. The company is a pioneer in liver disease research with a diverse R&D portfolio targeting conditions such as Acute-on-Chronic Liver Failure, cholangiocarcinoma, and urea cycle disorder. GENFIT is headquartered in Lille, France, and has offices in Paris, Zurich, and Cambridge, MA.
YTD Price Performance: -4.96%
Average Trading Volume: 13,052
Technical Sentiment Signal: Buy
Current Market Cap: $185.1M
For detailed information about GNFT stock, go to TipRanks’ Stock Analysis page.